Abstract
We investigated the clinical efficacy and tolerability of 45 mg/day mosapride, a selective 5-hydroxytryptamine type 4 (5-HT4) agonist, in an open-label study involving five patients with Parkinson's disease (PD) who had response fluctuations (RFs). 'On' time and motor function scores were determined, and gastric motility was measured by a radionuclide gastric emptying (GE) test, the most reliable quantitative method available. We found that mosapride therapy significantly shortened GE half-time, reduced RFs, and improved motor functions in all patients. There were no adverse reactions. We conclude that selective 5-HT4 agonist therapy is beneficial for patients with PD who have RFs.
MeSH terms
-
Aged
-
Antiparkinson Agents / blood
-
Antiparkinson Agents / pharmacokinetics
-
Benzamides / adverse effects
-
Benzamides / therapeutic use*
-
Female
-
Gastric Emptying / drug effects
-
Gastrointestinal Motility / physiology*
-
Humans
-
Levodopa / blood
-
Levodopa / pharmacokinetics
-
Morpholines / adverse effects
-
Morpholines / therapeutic use*
-
Parkinson Disease / diagnostic imaging
-
Parkinson Disease / drug therapy*
-
Parkinson Disease / physiopathology*
-
Positron-Emission Tomography
-
Receptors, Serotonin, 5-HT4 / drug effects*
-
Serotonin Receptor Agonists / therapeutic use*
-
Stomach / diagnostic imaging
Substances
-
Antiparkinson Agents
-
Benzamides
-
Morpholines
-
Serotonin Receptor Agonists
-
Receptors, Serotonin, 5-HT4
-
Levodopa
-
mosapride